Background: Within Severe Asthma (SA) many biologic treatments exist, however amongst European countries with distinct healthcare systems, and varying access to biologics, there is minimal data to describe treatment decisions.

Aims: Describe real-world biologic treatment patterns within a SA population.

Methods: Real-world data were collected from a retrospective, global database of healthcare provider (HCP)-reported electronic patient medical forms, abstracted from a representative sample of HCP treating SA patients across France, Germany, Italy, Spain, and the UK. Included patients had a SA diagnosis between January 1992 ? May 2022 with the earliest prescribed biologic used as index. Biologic initiation and switches post index are reported here.

Results: Across all countries (N=1,800), majority of patients were female (54%) within the 41-64 age group (53%). Omalizumab was the most prescribed index biologic, except within the UK (mepolizumab). Overall, switching was minimal; however, Spain, Italy, and France had the greatest proportion of patients who switched. Mepolizumab was the most prescribed 2^nd biologic in Spain, benralizumab was preferred in France and Italy, and dupilumab in the UK.

Conclusions: Omalizumab was the most prescribed index biologic across all countries, except the UK. Biologic selection for patients who switched varied, however benralizumab or dupilumab were favored across all, except Spain.

Funding: GSK:218228